As the US awaits the 2023 launch of adalimumab biosimilars, Biogen announces an injunction against Sandoz over a natalizumab biosimilar, Rani Therapeutics initiates a development program for an oral ustekinumab biosimilar, and Bio-Thera Solutions begins a phase 3 trial for a secukinumab biosimilar.
As the rest of the biosimilar industry prepares for adalimumab biosimilars to launch in the United States next year, Biogen announces an injunction against Sandoz over a natalizumab biosimilar, Rani Therapeutics initiates a development program for an oral ustekinumab biosimilar, and Bio-Thera Solutions begins a phase 3 trial for a secukinumab biosimilar.
Natalizumab Biosimilar Injunction
According to a report from Big Molecule Watch, Biogen is seeking a preliminary injunction in its Biologics Price Competition and Innovation Act (BPCIA) lawsuit against Sandoz. The case is related to Sandoz’ proposed biosimilar of Tysabri (natalizumab), a drug used to treat Crohn disease and multiple sclerosis.
Biogen’s motion will be completed by April 7, 2023, and a hearing is scheduled shortly after at the Court’s discretion. The company has also filed a redacted version of its 107-page sealed complaint against Sandoz, in which Biogen alleges that Sandoz has infringed 28 patents protected under the BPCIA in it biologics license application of PB006, its natalizumab biosimilar candidate.
Representatives from Biogen said the asserted patents are related to “inventions relating to Tysabri, including regarding therapeutic uses of Tysabri, ways of making treatment with Tysabri safer for patients and Biogen’s innovative methods of manufacturing antibodies, such as Tysabri.”
Oral Ustekinumab Biosimilar Development
Rani Therapeutics, a clinical stage biotherapeutics company based in California, announced that it has started the preclinical development process for RT-111, a RaniPill GO capsule using an ustekinumab biosimilar.
The biosimilar references Stelara, which is used to treat moderate to severe plaque psoriasis, active psoriatic arthritis, moderate to severe Crohn disease, and moderate to severe ulcerative colitis, all of which have an unmet need for oral therapies.
“Ustekinumab has helped thousands of patients with inflammatory autoimmune diseases, but today the treatment requires regular long-term injections. Rani is developing RT-111, an orally administered ustekinumab biosimilar, with the goal of reducing the burden of treatment and improving outcomes for patients. We are increasingly excited about the potential of the RaniPill platform to provide patients with oral replacements to current injectable standards of care, and we expect that RT-111 will be the first of many expansions of our pipeline,” said Talat Imran, CEO of Rani Therapeutics in a company statement.
Rani Therapeutics has developed and tested the RaniPill capsule, an oral delivery platform that can administer any drug, including large molecules, such as peptides, proteins, and antibodies. The RaniPill Go can deliver up to 3 mg of a drug with high bioavailability. Rani Therapeutics is also working on a high-capacity RaniPill device (RaniPill HC) that can deliver payloads of up to 20 mg with high bioavailability.
Phase 3 Trial for Secukinumab Biosimilar
Bio-Thera Solutions shared that it had initiated a phase 3 trial for its secukinumab biosimilar candidate (BAT2306) that references Cosentyx. The randomized, double-blind, parallel group, active control study will compare the efficacy and safety of the biosimilar and the reference product in patients with moderate to severe plaque psoriasis.
Secukinumab is a human immunoglobulin G1k monoclonal antibody that binds to interleukin-17A. Cosentyx is used in the treatment of adult and pediatric patients with plaque psoriasis, active enthesitis-related arthritis, and active psoriatic arthritis. It’s also indicated for treating adult patients with active nonradiographic axial spondyloarthritis and active ankylosing spondylitis.
Bio-Thera said that after the trial is completed, it will file for regulatory approval for all indications of the reference product in the European Union, United Kingdom, China, and United States. In addition to BAT2306, Bio-Thera is developing biosimilars referencing Actemra (tocilizumab), Simponi (golimumab), Stelara, and Nucala (mepolizumab). Qletli, a biosimilar referencing Humira (adalimumab), and Pobevcy, a biosimilar for Avastin (bevacizumab), have been approved and are marketed in China.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Switching Patterns Highlight Nocebo Effect in European Patients Using Amgevita
July 23rd 2024About half of the patients in a European study who transitioned from reference adalimumab to a biosimilar version stayed on the biosimilar at the 1-year mark. However, researchers warned about a possible nocebo effect resulting in some patients switching back to the originator.
Biosimilars Gastroenterology Roundup for May 2024—Podcast Edition
June 2nd 2024On this episode of Not So Different, we review the biggest gastroenterology biosimilar stories from May 2024, covering new data from conferences and journals on infliximab and adalimumab products that demonstrate positive clinical results and confirm the safety of these biosimilars, as well as the feasibility of switching to them.
Eye on Pharma: EU Biosimilar Approval, Launches and Product Returns, Denosumab Switching Data
July 10th 2024The European Union approves a tocilizumab biosimilar and the US sees another launch, Genentech’s ophthalmology biobetter returns to the market, and Samsung Bioepis shares data on switching to its denosumab biosimilar.